Eli Lilly and Company
https://www.lilly.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Digital Tech Convergence Is Transforming Health Care - LSX Panel
Leaders from Eli Lilly and Vertex Pharmaceuticals, 9amHealth, Features Capital, and accelerator PharmStars discussed the convergence of biopharma, medtech and healthtech, and what is needed to achieve health care transformation, in an LSX World Congress USA panel.
Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On
The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.
Vanda’s Tradipitant Gets CRL In Gastroparesis But Another NDA Filing Is Still On
The company will file a new drug application with the US FDA by the end of the year for tradipitant in a different indication, motion sickness.
ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?
The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- Hypnion
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice